• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Kahn Swick & Foti

Kahn Swick & Foti represents investors in securities fraud class actions, as well as shareholders and consumers harmed by corporate wrongdoing.

  • About Us
    • About Our Firm
    • Institutional Investor Services
    • KSF in the Community
    • Careers at KSF
    • Contact Us
  • Attorneys
  • Practice Areas
    • Securities Class Action Litigation
    • Corporate Governance And Derivative Litigation
    • Consumer Protection Litigation
    • Shareholder Mergers and Acquisitions Class Action Litigation
    • Antitrust Litigation
  • Current Cases
  • KSF News
  • Client Login
  • Asset Recovery Services
  • Contact KSF

Lead Plaintiffs Defeat Motion to Dismiss in Part in Shanawaz v. Intellipharmaceutics International Inc.

Home»News»Lead Plaintiffs Defeat Motion to Dismiss in Part in Shanawaz v. Intellipharmaceutics International Inc.

Shanawaz v. Intellipharmaceutics International Inc., et al., No. 1:17-cv-5761 (S.D.N.Y.). On December 17, 2018, the Hon. J. Paul Oetken, United States District Court Judge for the Southern District of New York, entered an Opinion and Order denying, in part, defendants’ motion to dismiss. This matter stems from alleged material misrepresentations and omissions made by defendants in describing the content and scope of studies included in the Rexista™ New Drug Application (“NDA”). In his opinion, Judge Oetken held that lead plaintiffs had stated facts with sufficient particularity to plausibly alleged that defendants had violated Section 10(b), Rule 10b-5, and Section 20(a) of the Securities Exchange Act of 1934.

Filed Under: News

Previous Post: « Final Judgment of $14.75 Million Entered in Eletrobras Securities Litigation
Next Post: Delaware Chancery Court Denies Motion to Dismiss Fitbit Inc. Insider Trading Case »

Primary Sidebar

Current Cases

Cabot Oil & Gas Corporation (NYSE: COG)

Amyris, Inc. (NasdaqGS: AMRS)

Obalon Therapeutics, Inc. (NasdaqGS: OBLN)

Coherent, Inc. (NasdaqGS: COHR)

Penumbra, Inc. (NYSE: PEN)

Anchiano Therapeutics Ltd. (NasdaqGS: ANCN)

see more»
 

Join Our Mailing List

To receive news of interest to shareholders and consumers and learn about potential new cases, you may join our mailing list by entering your email below.

Terms and Conditions | Privacy Notice

© 2006-2021 Copyright. All rights reserved Kahn Swick & Foti LLC · New Orleans · New York — Kahn Swick & Foti LLP · San Francisco

We recently updated our Privacy Policy. We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.OkPrivacy policy